In 2012, an Italian Named Patient Program began for hepatitis C virus (HCV)-infected liver transplant (LT) recipients with advanced fibrosis, before approval of direct antiviral agents (DAA), to benefit severely ill patients. The aim of this "real-life" study was to assess treatment efficacy and safety with an extended course of daclatasvir (DCV) plus sofosbuvir (SOF) with or without ribavirin (RBV).

Lionetti, R., Calvaruso, V., Piccolo, P., Mancusi, R.l., Mazzarelli, C., Fagiuoli, S., et al. (2018). Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study. CLINICAL TRANSPLANTATION, 32(2), e13165 [10.1111/ctr.13165].

Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study

MONTALBANO DI FILIPPO, MARGHERITA
;
LENCI, ILARIA
;
VALENTE, GABRIELLA
;
Angelico M.
;
2018

Abstract

In 2012, an Italian Named Patient Program began for hepatitis C virus (HCV)-infected liver transplant (LT) recipients with advanced fibrosis, before approval of direct antiviral agents (DAA), to benefit severely ill patients. The aim of this "real-life" study was to assess treatment efficacy and safety with an extended course of daclatasvir (DCV) plus sofosbuvir (SOF) with or without ribavirin (RBV).
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/12 - Gastroenterologia
English
Con Impact Factor ISI
antiviral treatment; cirrhosis; direct antiviral agents; hepatitis C virus; liver transplantation
Lionetti, R., Calvaruso, V., Piccolo, P., Mancusi, R.l., Mazzarelli, C., Fagiuoli, S., et al. (2018). Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study. CLINICAL TRANSPLANTATION, 32(2), e13165 [10.1111/ctr.13165].
Lionetti, R; Calvaruso, V; Piccolo, P; Mancusi, Rl; Mazzarelli, C; Fagiuoli, S; MONTALBANO DI FILIPPO, M; Lenci, I; Carrai, P; Guaraldi, G; Visco-Comandini, U; Milana, M; Biolato, M; Loiacono, L; Valente, G; Craxi, A; Angelico, M; D'Offizi, G
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/194484
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact